Sinovac Biotech Holds Annual General Meeting

BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA),
a leading provider of vaccines in China, today announced that its Annual
General Meeting originally scheduled for March 25, 2008 was held two weeks
later, on April 8, 2008.
During the April 8, 2008 Annual General Meeting, held at Sinovac's
headquarters located at No. 39, Shangdi Xi Rd., Haidian District, Beijing,
PRC,
resolutions for the re-election of directors were passed, the Company's 2006
Annual Report was reviewed, and the appointment of Ernst & Young as Sinovac's
registered public accountants was approved.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's vaccines
include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B),
Anflu(R) (influenza) and Panflu(TM)(H5N1). Sinovac is currently developing
Universal Pandemic Influenza vaccin and Japanese encephalitis vaccine.
Additional information about Sinovac is available on its website,
http://www.sinovac.com . To be added to our distribution list, please email:
info@sinovac.com.
For more information, please contact:

Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x871
Fax: +86-10-6296-6910
Email: info@sinovac.com

Investors/Media:
Stephanie Carrington/Janine McCargo
The Ruth Group
Tel: +1-646-536-7017/7033
Email: scarrington@theruthgroup.com
jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Helen G. Yang of Sinovac Biotech Ltd., +86-10-8289-0088 x871, or fax,
+86-10-6296-6910, or email, info@sinovac.com; Investors, Stephanie Carrington
of The Ruth Group, +1-646-536-7017, or scarrington@theruthgroup.com; Media,
Janine McCargo of The Ruth Group, +1-646-536-7033, or
jmccargo@theruthgroup.com, all for Sinovac Biotech Ltd.